RL
Rallybio Corporation
RLYB · NASDAQ
$16.92 +0.42% (+$0.07)
1M +0.71%
Market Cap $89.8M
P/E Ratio 1.97x
Div. Yield -
ROE 68.56%
Bulios Fair Price
$10.42
38.4% downside
Current Price
$16.92
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RLYB is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
85 /100
Cheap P/E 1.97x
P/S 139.00x
P/FCF 3.41x
Growth
0 /100
Declining Book val. growth 30.05%
EPS growth N/A
Rev. growth N/A
Profitability
50 /100
Moderate Gross margin 1,107.59%
Net margin 7,051.24%
FCF margin 4,077.40%
Quality
45 /100
Average ROIC 24.40%
ROE 68.56%
Asset turnover 0.01x
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 27.26x
Net debt/EBITDA -3.44x
Stability
42 /100
Moderate Beta -0.85x
EPS volatility 38.47%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RLYB
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stephen Uden
Employees
7
Headquarters
New Haven
Upcoming events
05 NOV
Earnings
Upcoming earnings report